Investor Presentaiton

RETATRUTIDE DEMONSTRATED A MEAN WEIGHT REDUCTION OF UP TO 24.2% AT 48 WEEKS Percent change in body weight (%) 10 -10 EFFICACY RESULTS 48 -30 36 1 4 8 12 16 20 24 Weeks since Randomization -2.1% -8.7% -16.3% -17.8% -21.7% -23.9% -24.2% Placebo RETA 1 mg RETA 8 mg [ID 2 mg] RETA 4 mg [ID 2 mg] RETA 4 mg [ID 4 mg] RETA 8 mg [ID 4 mg] Not for promotional use RETA 12 mg [ID 2 mg] KEY MESSAGES Lilly In the Phase 2 trial of adults with overweight and obesity, treatment was associated with improvements in cardiometabolic and hepatic measures at weeks 24 and 48 Safety profile was similar to other incretin-based therapies. Initiated the TRIUMPH Phase 3 program, which includes multiple studies that will evaluate safety and efficacy for chronic weight management, obstructive sleep apnea, and knee osteoarthritis in people with overweight and obesity In a Phase 2 trial in type 2 diabetes, participants achieved an HbA1c reduction of up to 2.0% on average; plan to advance retatrutide into Phase 3 for type 2 diabetes 2023 Q2 EARNINGS 16

View entire presentation